TechnoVax Inc. Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate
7/18/2007 10:46:29 AM
TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax Inc., a vaccine biotechnology company located in Tarrytown, NY presented results based on its novel virus-like particle (VLP) technology at the American Society for Virology Annual Meeting, being held at Oregon State University, Corvallis Oregon. Preclinical data on its 1918 VLP vaccine, designed to protect against the highly virulent 1918 pandemic influenza virus that killed approximately 50 million people worldwide, showed protection against a surrogate virus in animals. Also, TechnoVax, Inc. presented data on its novel bivalent VLP vaccine technology which creates VLP vaccines each bearing two antigenically distinct molecules. A single bivalent VLP will afford protecting against two antigenically distinct influenza viruses.
comments powered by